Skip to main content

Advertisement

SpringerLink
Log in

Estrogen and thrombosis: Controversies and common sense

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Soon after the introduction of hormonal oral contraceptive agents reports of thrombotic complications appeared. In the past several decades, large epidemiological studies helped defined these risks for both arterial and venous complications. Clinicians can assess a patient’s risk of thrombosis by both composition of the agent and patients’ personal risk factors. For women with bleeding disorders these prothrombotic changes can help decrease bleeding complications. There is now also abundant data on future management of patients with estrogen related thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost. 2003;1(7):1371–80.

    Article  PubMed  CAS  Google Scholar 

  2. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol. 2009;53(3):221–31.

    Article  PubMed  CAS  Google Scholar 

  3. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345(25):1787–93.

    Article  PubMed  CAS  Google Scholar 

  4. Hormones and cardiovascular health in women (2006) Hum Reprod Update 12(5): 483–497

    Google Scholar 

  5. Tanis BC. Oral contraceptives and the risk of myocardial infarction. Eur Heart J. 2003;24(5):377–80.

    Article  PubMed  CAS  Google Scholar 

  6. Seibert C, Barbouche E, Fagan J, Myint E, Wetterneck T, Wittemyer M. Prescribing oral contraceptives for women older than 35 years of age. Ann Intern Med. 2003;138(1):54–64.

    PubMed  Google Scholar 

  7. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33(5):1202–8.

    Article  PubMed  Google Scholar 

  8. Pitts SA, Emans SJ. Controversies in contraception. Curr Opin Pediatr. 2008;20(4):383–9.

    Article  PubMed  Google Scholar 

  9. van den Bosch MA, Kemmeren JM, Tanis BC, et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost. 2003;1(3):439–44.

    Article  Google Scholar 

  10. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.

    Article  PubMed  Google Scholar 

  11. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007;75(5):328–36.

    Article  PubMed  Google Scholar 

  12. Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol. 2007;14(5):488–93.

    PubMed  CAS  Google Scholar 

  13. van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.

    Article  Google Scholar 

  14. Sitruk-Ware R, Nath A (2011) Metabolic effects of contraceptive steroids. Reviews in endocrine and metabolic disorders In Press

  15. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772–80.

    Article  PubMed  CAS  Google Scholar 

  16. Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother. 2010;11(7):1147–57.

    Article  PubMed  CAS  Google Scholar 

  17. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007;110(3):587–93.

    Article  PubMed  CAS  Google Scholar 

  18. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323(7305):131–4.

    Article  PubMed  CAS  Google Scholar 

  19. Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol. 2000;49(6):580–90.

    Article  PubMed  CAS  Google Scholar 

  20. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World health organization collaborative study of cardiovascular disease and steroid hormone contraception (1995) Lancet 346(8990): 1582–1588

    Google Scholar 

  21. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–8.

    Article  PubMed  CAS  Google Scholar 

  22. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007;76(1):4–7.

    Article  PubMed  CAS  Google Scholar 

  23. Weiss N. Third-generation oral contraceptives: how risky? Lancet. 1995;346(8990):1570.

    Article  PubMed  CAS  Google Scholar 

  24. Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res. 2011;127S3:S30–4.

    Article  Google Scholar 

  25. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception. 2010;82(5):410–7.

    Article  PubMed  CAS  Google Scholar 

  26. Sehovic N, Smith KP. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann Pharmacother. 2010;44(5):898–903.

    Article  PubMed  CAS  Google Scholar 

  27. Pearce HM, Layton D, Wilton LV, Shakir SA. Deep vein thrombosis and pulmonary embolism reported in the prescription event monitoring study of Yasmin. Br J Clin Pharmacol. 2005;60(1):98–102.

    Article  PubMed  Google Scholar 

  28. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151

  29. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;342:d2139

  30. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344–54.

    Article  PubMed  CAS  Google Scholar 

  31. Dunn N. The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ. 2011;342:d2519

    Google Scholar 

  32. van Hylckama VA, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010;30(11):2297–300.

    Article  Google Scholar 

  33. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World health organization collaborative study of cardiovascular disease and steroid hormone contraception (1995) Lancet 346(8990): 1575–1582.

  34. Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception. 2010;81(5):452–3.

    Article  PubMed  Google Scholar 

  35. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81(5):408–13.

    Article  PubMed  CAS  Google Scholar 

  36. Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res. 2009;123(3):429–35.

    Article  PubMed  CAS  Google Scholar 

  37. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–74.

    Article  PubMed  Google Scholar 

  38. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344(20):1527–35.

    Article  PubMed  CAS  Google Scholar 

  39. de Groot AN, van Dongen PW, Vree TB, Eskes TK. Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant human menstruating uterus. Eur J Obstet Gynecol Reprod Biol. 1995;60(2):101–7.

    Article  PubMed  Google Scholar 

  40. DeSancho MT, Dorff T, Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis. 2010;21(6):534–8.

    Article  PubMed  CAS  Google Scholar 

  41. Blickstein D, Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gynecol. 2007;19(4):370–6.

    Article  PubMed  Google Scholar 

  42. Vandenbroucke JP, Van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? Brit Med J. 1996;313:1127–30.

    PubMed  CAS  Google Scholar 

  43. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res. 2010;126(1):5–11.

    Article  PubMed  CAS  Google Scholar 

  44. James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009;29(3):326–31.

    Article  PubMed  CAS  Google Scholar 

  45. Goebelsmann U, Mashchak CA, Mishell Jr DR. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol. 1985;151(7):868–77.

    PubMed  CAS  Google Scholar 

  46. Olie V, Canonico M, Scarabin PY. Postmenopausal hormone therapy and venous thromboembolism. Thromb Res. 2011;127 Suppl 3:S26–9.

    Article  PubMed  CAS  Google Scholar 

  47. Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception. 2008;78(6):451–8.

    Article  PubMed  CAS  Google Scholar 

  48. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood. 2004;103(3):927–33.

    Article  PubMed  CAS  Google Scholar 

  49. Grimes DA, Schulz KF, Raymond EG. Surrogate end points in women’s health research: science, protoscience, and pseudoscience. Fertil Steril. 2010;93(6):1731–4.

    Article  PubMed  Google Scholar 

  50. Martineau M, Nelson-Piercy C. Venous thromboembolic disease and pregnancy. Postgrad Med J. 2009;85(1007):489–94.

    Article  PubMed  CAS  Google Scholar 

  51. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999;353(9160):1258–65.

    Article  PubMed  CAS  Google Scholar 

  52. Royal College of Obstetricains and Gynaecologists (2010) Venous thromboembolism and hormonal contraception, Green-top Guideline No. 40., pp. 1–13

  53. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from royal college of general practitioners’ oral contraception study. Brit Med J. 2010;340:c927.

    Article  PubMed  Google Scholar 

  54. Hicks S, DeLoughery T, Edelman A. Menstrual regulation in women with von Willebrand’s disease. Int J Gynaecol Obstet. 2008;102(1):80–1.

    Article  PubMed  Google Scholar 

  55. Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf. 2008;31(4):275–82.

    Article  PubMed  CAS  Google Scholar 

  56. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625–32.

    Article  PubMed  CAS  Google Scholar 

  57. Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril. 2008;90(3):673–7.

    Article  PubMed  Google Scholar 

  58. Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011;83(3):242–7.

    Article  PubMed  CAS  Google Scholar 

  59. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352–61.

    Article  PubMed  CAS  Google Scholar 

  60. Lijfering WM, Veeger NJ, Middeldorp S, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood. 2009;114(10):2031–6.

    Article  PubMed  CAS  Google Scholar 

  61. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376(9757):2032–9.

    Article  PubMed  Google Scholar 

  62. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84(6):961–7.

    PubMed  CAS  Google Scholar 

  63. Zingone MM, Guirguis AB, Airee A, Cobb D. Probable drug interaction between warfarin and hormonal contraceptives. Ann Pharmacother. 2009;43(12):2096–102.

    Article  PubMed  Google Scholar 

  64. Dunn N. Oral contraceptives and venous thromboembolism. Brit Med J. 2009;339:b3164.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knight Cancer Center, Hematology/Laboratory Medicine, Departments of Medicine, Pathology, and Pediatrics, Oregon Health Sciences University, Hematology L586, 3181 SW Sam Jackson Park Road, Portland, OR, 97229–3098, USA

    Thomas G. DeLoughery

Authors
  1. Thomas G. DeLoughery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas G. DeLoughery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeLoughery, T.G. Estrogen and thrombosis: Controversies and common sense. Rev Endocr Metab Disord 12, 77–84 (2011). https://doi.org/10.1007/s11154-011-9178-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-011-9178-0

Keywords

Search

Navigation